Binding proteins recognizing ha-2 antigen and uses thereof
AssigneeTScan Therapeutics, Inc.
InventorsRibhu Nayar, Gavin MacBeath, Sonal Jangalwe, Mollie M. Jurewicz, Andrew S. Basinski, Qikai Xu, Antoine J. Boudot, Tomasz Kula
Life of this patent
Estimating the term…
Abstract
Provided herein are binding proteins recognizing HA-2 antigen and uses thereof.
Claims149
A binding protein comprising:
- a) a T cell receptor (TCR) alpha chain CDR sequence with at least about 80% identity to a TCR alpha chain CDR sequence selected from the group consisting of TCR alpha chain CDR sequences listed in Table 1;
- and/or
- b) a TCR beta chain CDR sequence with at least about 80% identity to a TCR beta chain CDR sequence selected from the group consisting of TCR beta chain CDR sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.
A binding protein comprising:
- a) a TCR alpha chain variable (Vα) domain sequence with at least about 80% identity to a TCR Vα domain sequence selected from the group consisting of TCR Vα domain sequences listed in Table 1;
- and/or
- b) a TCR beta chain variable (Vβ) domain sequence with at least about 80% identity to a TCR Vβ domain sequence selected from the group consisting of TCR Vβ domain sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.
A binding protein comprising:
- a) a TCR alpha chain sequence with at least about 80% identity to a TCR alpha chain sequence selected from the group consisting of TCR alpha chain sequences listed in Table 1;
- and/or
- b) a TCR beta chain sequence with at least about 80% identity to a TCR beta chain sequence selected from the group consisting of TCR beta chain sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.
A binding protein comprising:
- a) a TCR alpha chain CDR sequence selected from the group consisting of TCR alpha chain CDR sequences listed in Table 1;
- and/or
- b) a TCR beta chain CDR sequence selected from the group consisting of TCR beta chain CDR sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.
A binding protein comprising:
- a) a TCR alpha chain variable (Vα) domain sequence selected from the group consisting of TCR Vα domain sequences listed in Table 1;
- and/or
- b) a TCR beta chain variable (Vβ) domain sequence selected from the group consisting of TCR Vβ domain sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.
A binding protein comprising:
- a) a TCR alpha chain sequence selected from the group consisting of TCR alpha chain sequences listed in Table 1;
- and/or
- b) a TCR beta chain sequence selected from the group consisting of TCR beta chain sequences listed in Table 1, wherein the binding protein is capable of binding to an HA-2 immunogenic peptide-MHC (pMHC) complex, optionally wherein the binding affinity has a Kd less than or equal to about 5×10−4 M.
A TCR alpha chain and/or beta chain selected from the group consisting of TCR alpha chain and beta chain sequences listed in Table 1.
An isolated nucleic acid molecule that hybridizes, under stringent conditions, with the complement of a nucleic acid encoding a polypeptide selected from the group consisting of polypeptide sequences listed in Table 1, or a sequence with at least about 80% homology to a nucleic acid encoding a polypeptide selected from the group consisting of the polypeptide sequences listed in Table 1, optionally wherein the isolated nucleic acid molecule comprises 1) a TRAV, TRAJ, and/or TRAC gene or fragment thereof selected from the group of TRAV, TRAJ, and TRAC genes listed in Table 1 and/or 2) a TRBV, TRBJ, and/or TRBC gene or fragment thereof selected from the group of TRBV, TRBJ, and TRBC genes listed in Table 1.
An expression vector comprising a promoter operably linked to a nucleic acid sequence encoding CD8α and/or CD8β.
Dependencies are inferred from the claim text.